<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>9
<FILENAME>exhibit991.txt
<DESCRIPTION>PRESS RELEASE
<TEXT>
PRESS RELEASE                            LIFE SCIENCES RESEARCH, INC.
                                         (OTCBB: LSRI)
                                         PO Box 2360
                                         Mettlers Road
                                         East Millstone, NJ 08875-2360

                                         For Further Information:
                                         Richard Michaelson
                                         Phone:   US: (732) 649-9961
                                         e-mail: LifeSciencesResearch@LSRinc.net


June 14, 2005

                    LSR ANNOUNCES FULL REPAYMENT OF BANK DEBT
               WITH PROCEEDS FROM SALE LEASEBACK AND INTERNAL CASH

East Millstone, New Jersey, June 14, 2005 - Life Sciences Research, Inc. (OTCBB:
LSRI) announced today that it paid in full its outstanding bank  indebtedness of
(pound)22.6  million  (approximately  $41.3 million) using the proceeds from the
sale-leaseback of its three operating facilities and cash on hand.

The  sale-leaseback  was entered  into with  Alconbury  Estates,  an  investment
company controlled by Andrew Baker, the Company's Chairman and CEO. The purchase
price for the three  facilities was $40 million,  consisting of $30 million cash
at closing and a five year $10 million  variable  rate  subordinated  promissory
note,  which  Alconbury  has agreed to make a best effort to repay within twelve
months. The Company has entered into  corresponding  leases for those facilities
for 30 years, with 2 five-year options,  with rentals commencing at $1.8 million
per year for the New Jersey  facility and (pound)1.7  million ($3.1 million) for
the  two  U.K.  facilities.  Net  costs  to the  Company  associated  with  this
transaction  were  approximately  $1 million.  Costs  incurred by Alconbury were
approximately $4.5 million, which was paid by the Company, but will be repaid by
Alconbury as agreed.

Brian Cass, LSR's President and Managing Director said "As we have stated in our
public filings since 2001, we have long seen the benefits of leveraging our real
estate assets for long term financing, as well as to better position the Company
for future growth. This transaction,  which was made possible by the efforts and
commitment of the Company's Chairman,  achieved important  strategic  objectives
for the Company.  We have fully repaid our bank debt which was coming due in one
year and have  effectively  provided  secure long term financing in exchange for
paying rent. Moreover, we have done so while ensuring the continued availability
of our core operating facilities to the Company for the foreseeable future. This
structure  could  also be  considered  as a  financing  mechanism  for  possible
facility expansion for our Company should we so desire in the future."

In accordance with the provisions of FASB  Interpretation  No. 46R (FIN 46), the
Company will reflect the  consolidation  of Alconbury  Estates into its accounts
until such time as the $10 million subordinated note has been repaid. Although a
significant  ongoing  impact of that  consolidation  will be  eliminated  by the
minority interest entries  associated with this  transaction,  it will mean that
the Company  will not record the gain and loss  associated  with the sale of the
properties, nor recognize the associated decrease in depreciation,  until FIN 46
consolidation  accounting  no longer  applies.  At that time,  the Company  will
record a  non-cash  loss of  approximately  $44  million  for the sale of the UK
properties,  and a gain of approximately $6 million,  amortized over the term of
the lease, for the US property. In addition, the Company anticipates a reduction
in its annual depreciation charge of approximately $3.5 million.

Life  Sciences  Research,  Inc.  is  a  global  contract  research  organization
providing product development  services to the pharmaceutical,  agrochemical and
biotechnology  industries.  LSR brings  leading  technology  and  capability  to
support its clients in  non-clinical  safety  testing of new  compounds in early
stage development and assessment.  The purpose of this work is to identify risks
to humans, animals or the environment resulting from the use or manufacture of a
wide  range of  chemicals  which  are  essential  components  of LSR's  clients'
products.   The  Company's   services  are  designed  to  meet  the   regulatory
requirements of governments  around the world. LSR operates research  facilities
in the United States (the Princeton  Research Center, New Jersey) and the United
Kingdom (Huntingdon and Eye, England).

This announcement  contains statements that may be forward-looking as defined by
the Private Securities Litigation Reform Act of 1995. These statements are based
largely  on  LSR's  expectations  and are  subject  to a  number  of  risks  and
uncertainties,  certain of which are beyond our control, as more fully described
in the Company's SEC filings,  including its Form 10-K for the fiscal year ended
December 31, 2004, as filed with the US Securities and Exchange Commission.


                                   --- end ---
</TEXT>
</DOCUMENT>